DK1425280T3 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK1425280T3
DK1425280T3 DK02764696T DK02764696T DK1425280T3 DK 1425280 T3 DK1425280 T3 DK 1425280T3 DK 02764696 T DK02764696 T DK 02764696T DK 02764696 T DK02764696 T DK 02764696T DK 1425280 T3 DK1425280 T3 DK 1425280T3
Authority
DK
Denmark
Prior art keywords
alkyl
halo
alkoxy
halogen
hydrogen
Prior art date
Application number
DK02764696T
Other languages
Danish (da)
English (en)
Inventor
Fabio Romano Di
Fabrizio Micheli
Yves St-Denis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1425280T3 publication Critical patent/DK1425280T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02764696T 2001-07-17 2002-07-15 Kemiske forbindelser DK1425280T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117396.2A GB0117396D0 (en) 2001-07-17 2001-07-17 Chemical compounds

Publications (1)

Publication Number Publication Date
DK1425280T3 true DK1425280T3 (da) 2007-01-02

Family

ID=9918655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02764696T DK1425280T3 (da) 2001-07-17 2002-07-15 Kemiske forbindelser

Country Status (27)

Country Link
US (2) US7253284B2 (ro)
EP (2) EP1425280B1 (ro)
JP (1) JP4459616B2 (ro)
KR (2) KR100961287B1 (ro)
CN (1) CN100447141C (ro)
AT (2) ATE338042T1 (ro)
AU (1) AU2002328899B2 (ro)
BR (1) BR0211171A (ro)
CA (1) CA2451530A1 (ro)
CO (1) CO5550437A2 (ro)
CY (1) CY1105780T1 (ro)
DE (2) DE60214401T2 (ro)
DK (1) DK1425280T3 (ro)
ES (2) ES2342417T3 (ro)
GB (2) GB0117396D0 (ro)
HK (1) HK1066535A1 (ro)
HU (1) HUP0400465A2 (ro)
IL (1) IL159254A0 (ro)
MX (1) MXPA04000494A (ro)
NO (1) NO20040206L (ro)
NZ (1) NZ530043A (ro)
PL (1) PL368053A1 (ro)
PT (1) PT1425280E (ro)
RU (1) RU2310655C2 (ro)
SI (1) SI1425280T1 (ro)
WO (1) WO2003008412A2 (ro)
ZA (1) ZA200309708B (ro)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
WO2004062665A1 (en) * 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
BRPI0417943A (pt) 2003-12-22 2007-04-17 Sb Pharmco Inc antagonistas de receptor de crf e métodos relacionados para essa finalidade
EP1802621B1 (en) * 2004-10-19 2009-05-06 SmithKline Beecham (Cork) Limited Crf receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8513420B2 (en) 2007-03-19 2013-08-20 Monika Mazik Amino-naphthyridine derivatives
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
WO2009008552A1 (en) * 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
GB2248618B (en) 1988-06-17 1993-01-06 Wyeth John & Brother Ltd Process for preparing pyridine derivatives
CA2022408A1 (en) 1989-08-31 1991-03-01 Michael P. Bodman Process for preparing pyridine carboxylic acid derivatives
ATE139232T1 (de) 1989-10-11 1996-06-15 Teijin Ltd Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE4022414A1 (de) 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
WO1992012718A1 (en) 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
PT633886E (pt) 1992-04-03 2001-03-30 Upjohn Co Aminas biciclicas-heterociclicas farmaceuticamente activas
JPH0710876A (ja) 1993-06-24 1995-01-13 Teijin Ltd ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
AU738304B2 (en) 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
DK0920429T3 (da) 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
AU735401B2 (en) * 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
EP0970082A2 (en) 1997-02-18 2000-01-12 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
WO1999007703A1 (en) 1997-08-05 1999-02-18 Pfizer Products Inc. 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
JPH11335376A (ja) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
JP2000086663A (ja) 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
WO2000058307A2 (en) 1999-03-11 2000-10-05 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
US6413982B1 (en) 1999-03-29 2002-07-02 Neurogen Corporation 4-substituted quinoline derivatives
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
US6525067B1 (en) 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
EA200200688A1 (ru) 2000-01-18 2003-02-27 Пфайзер Продактс Инк. Антагонисты фактора, высвобождающего кортикотропин
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
WO2002019975A1 (fr) 2000-09-05 2002-03-14 Taisho Pharmaceutical Co., Ltd. Stimulants de la croissance des cheveux
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1383747B1 (en) 2001-04-30 2008-02-20 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2004062665A1 (en) 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
TW200418830A (en) 2003-02-14 2004-10-01 Wyeth Corp Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
MXPA04000494A (es) 2004-05-04
KR100961287B1 (ko) 2010-06-04
CY1105780T1 (el) 2011-02-02
EP1695974B1 (en) 2010-03-17
ES2271327T3 (es) 2007-04-16
US20040171607A1 (en) 2004-09-02
HK1066535A1 (en) 2005-03-24
GB2378702A (en) 2003-02-19
ZA200309708B (en) 2005-01-21
CO5550437A2 (es) 2005-08-31
RU2004104349A (ru) 2005-03-27
KR20090110386A (ko) 2009-10-21
NO20040206L (no) 2004-03-16
EP1425280A2 (en) 2004-06-09
DE60214401D1 (de) 2006-10-12
IL159254A0 (en) 2004-06-01
WO2003008412A3 (en) 2003-05-01
DE60214401T2 (de) 2007-02-22
SI1425280T1 (sl) 2006-12-31
EP1425280B1 (en) 2006-08-30
GB0216041D0 (en) 2002-08-21
CN100447141C (zh) 2008-12-31
EP1695974A1 (en) 2006-08-30
RU2310655C2 (ru) 2007-11-20
PL368053A1 (en) 2005-03-21
ATE461197T1 (de) 2010-04-15
KR20040023651A (ko) 2004-03-18
GB0117396D0 (en) 2001-09-05
US20070219232A1 (en) 2007-09-20
CA2451530A1 (en) 2003-01-30
ES2342417T3 (es) 2010-07-06
US7253284B2 (en) 2007-08-07
AU2002328899B2 (en) 2006-12-21
JP4459616B2 (ja) 2010-04-28
PT1425280E (pt) 2006-12-29
CN1525972A (zh) 2004-09-01
BR0211171A (pt) 2004-08-10
DE60235729D1 (de) 2010-04-29
JP2005514328A (ja) 2005-05-19
ATE338042T1 (de) 2006-09-15
WO2003008412A2 (en) 2003-01-30
NZ530043A (en) 2006-03-31
HUP0400465A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
DK1425280T3 (da) Kemiske forbindelser
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
TW200508232A (en) Bicyclic derivatives, their preparation, pharmaceutical compositions containing them and their use in therapy
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
NO20061170L (no) Piperazinderivater for behandling av HIV-infeksjoner
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20055977L (no) Nye benzimidazolderivater
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
NO20035583D0 (no) Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
ATE401080T1 (de) (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
NO20040203L (no) Kjemiske forbindelser
TH101406B (th) สารประกอบตัวใหม่
DK1065206T3 (da) Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler